Skip to main content
PMC home page
Cancer Science logoLink to Cancer Science
. 2005 Aug 19;95(12):962–968. doi: 10.1111/j.1349-7006.2004.tb03184.x

Promoter methylation profiling of 30 genes in human malignant melanoma

Junichi Furuta 1,2, Yoshihiro Umebayashi 2, Kazuaki Miyamoto 1, Kanako Kikuchi 3, Fujio Otsuka 2, Takashi Sugimura 1, Toshikazu Ushijima 1,✉
PMCID: PMC11160084  PMID: 15596045

Abstract

Aberrant methylation and demethylation of promoter CpG islands lead to silencing of tumor‐suppressor genes and abnormal expression of normally methylated genes, respectively. Here, we analyzed human melanomas for their methylation and demethylation profiles. Methylation status of core regions in promoter CpG islands was examined for 20 (candidate) tumor‐suppressor genes, 4 genes that are not considered as tumor‐suppressors, but are frequently silenced in human cancers, and 6 normally methylated melanoma antigen genes (MAGEs). Analysis of 13 melanoma cell lines and 2 cultured normal human epidermal melanocytes (HEMs) showed that 9 tumor‐suppressor genes and all 4 non‐tumor‐suppressor genes were methylated in at least 1 cell line, but never in HEMs, and that all 6 MAGE genes were demethylated in 3 to 13 cell lines. Interestingly, we detected no methylation of MGMT, PTEN, MTAP and p27, which were previously reported as silenced in melanomas. Furthermore, 3 genes that were frequently methylated in the cell lines and 6 MAGE genes were analyzed in 25 surgical melanoma samples. RARB, RASSF1A and 3‐OST‐2 were methylated in 5 (20%), 9 (36%) and 14 (56%) samples, respectively. MAGE‐A1, A2, A3, B2, C1 and C2 were demethylated in 9 (36%), 22 (88%), 20 (80%), 7 (28%), 21 (84%) and 16 (64%) samples, respectively. At least 1 gene was methylated in 18 (72%) samples and at least 1 was demethylated in 24 (96%) samples. No correlation between frequent methylation and frequent demethylation was observed. These profiles showed that both aberrant methylation and demethylation occur widely in human melanomas.

References

  • 1. Li E. Chromatin modification and epigenetic reprogramming in mammalian development. Nat Rev Genet 2002; 3: 662–73. [DOI] [PubMed] [Google Scholar]
  • 2. Herman JG, Baylin SB. Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 2003; 349: 2042–54. [DOI] [PubMed] [Google Scholar]
  • 3. Merlo A, Herman JG, Mao L, Lee DJ, Gabrielson E, Burger PC, Baylin SB, Sidransky D. 5′ CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTSl in human cancers. Nat Med 1995; 1: 686–92. [DOI] [PubMed] [Google Scholar]
  • 4. Yoshiura K, Kanai Y, Ochiai A, Shimoyama Y, Sugimura T, Hirohashi S. Silencing of the E‐cadherin invasion‐suppressor gene by CpG methylation in human carcinomas. Proc Natl Acad Sci USA 1995; 92: 7416–9. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5. Kane ME, Loda M, Gaida GM, Lipman J, Mishra R, Goldman H, Jessup JM, Kolodner R. Methylation of the hMLHl promoter correlates with lack of expression of hMLHl in sporadic colon tumors and mismatch repair‐defective human tumor cell lines. Cancer Res 1997; 57: 808–11. [PubMed] [Google Scholar]
  • 6. Jurgens B, Schmitz‐Drager BJ, Schulz WA. Hypomethylation of LI LINE sequences prevailing in human urothelial carcinoma. Cancer Res 1996; 56: 5698–703. [PubMed] [Google Scholar]
  • 7. Takai D, Yagi Y, Habib N, Sugimura T, Ushijima T. Hypomethylation of LINE1 retrotransposon in human hepatocellular carcinomas, but not in surrounding liver cirrhosis. Jpn J Clin Oncol 2000; 30: 306–9. [DOI] [PubMed] [Google Scholar]
  • 8. Gama‐Sosa MA, Slagel VA, Trewyn RW, Oxenhandler R, Kuo KC, Gehrke CW, Ehrlich M. The 5‐methylcytosine content of DNA from human tumors. Nucleic Acids Res 1983; 11: 6883–94. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9. Kaneda A, Tsukamoto T, Takamura‐Enya T, Watanabe N, Kaminishi M, Sugimura T, Tatematsu M, Ushijima T. Frequent hypomethylation in multiple promoter CpG islands is associated with global hypomethylation, but not with frequent promoter hypermethylation. Cancer Sci 2004; 95: 58–64. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10. Zendman AJ, Ruiter DJ, van Muijen GN. Cancer/testis‐associated genes: identification, expression profile, and putative function. J Cell Physiol 2003; 194: 272–88. [DOI] [PubMed] [Google Scholar]
  • 11. de Smet C, Lurquin C, Lethe B, Martelange V, Boon T. DNA methylation is the primary silencing mechanism for a set of germ line‐ and tumor‐specific genes with a CpG‐rich promoter. Mol Cell Biol 1999; 19: 7327–35. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12. Cho B, Lee H, Jeong S, Bang YJ, Lee HJ, Hwang KS, Kim HY, Lee YS, Kang GH, Jeoung DI. Promoter hypomethylation of a novel cancer/testis antigen gene CAGE is correlated with its aberrant expression and is seen in premalignant stage of gastric carcinoma. Biochem Biophys Res Commun 2003; 307: 52–63. [DOI] [PubMed] [Google Scholar]
  • 13. Tucker MA, Goldstein AM. Melanoma etiology: where are we Oncogene 2003; 22: 3042–52. [DOI] [PubMed] [Google Scholar]
  • 14. 1 Epigenetic PTEN silencing in malignant melanomas without PTEN mutation. Am J Pathol 2000; 157: 1123–8. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15. Worm J, Bartkova J, Kirkin AF, Straten P, Zeuthen J, Bartek J, Guldberg P. Aberrant p27Kipl promoter methylation in malignant melanoma. Oncogene 2000; 19:5111–5. [DOI] [PubMed] [Google Scholar]
  • 16. Behrmann I, Wallner S, Komyod W, Heinrich PC, Schuierer M, Buettner R, Bosserhoff AK. Characterization of methylthioadenosine phosphorylase (MTAP) expression in malignant melanoma. Am J Pathol 2003; 163: 683–90. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17. Spugnardi M, Tommasi S, Dammann R, Pfeifer GP, Hoon DS. Epigenetic inactivation of RAS association domain family protein 1 (RASSF1A) in malignant cutaneous melanoma. Cancer Res 2003; 63: 1639–43. [PubMed] [Google Scholar]
  • 18. Paz MF, Fraga MF, Avila S, Guo M, Pollan M, Herman JG, Esteller M. A systematic profile of DNA methylation in human cancer cell lines. Cancer Res 2003; 63: 1114–21. [PubMed] [Google Scholar]
  • 19. Hoon DS, Spugnardi M, Kuo C, Huang SK, Morton DL, Taback B. Profiling epigenetic inactivation of tumor suppressor genes in tumors and plasma from cutaneous melanoma patients. Oncogene 2004; 23: 4014–22. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20. 1 Low frequency of p16/CDKN2A methylation in sporadic melanoma: comparative approaches for methylation analysis of primary tumors. Cancer Res 1997; 57: 5336–47. [PubMed] [Google Scholar]
  • 21. 1 p16INK4a inactivation is not frequent in uncultured sporadic primary cutaneous melanoma. Oncogene 1999; 18: 2527–32. [DOI] [PubMed] [Google Scholar]
  • 22. 1 Transcription of the MAGE‐1 gene and the methylation status of its Ets binding promoter elements: a quantitative analysis in melanoma cell lines using a real‐time polymerase chain reaction technique. Melanoma Res 1999; 9: 213–22. [DOI] [PubMed] [Google Scholar]
  • 23. Kinoshita H, Shi Y, Sandefur C, Meisner LF, Chang C, Choon A, Reznikoff CR, Bova GS, Friedl A, Jarrard DF. Methylation of the androgen receptor minimal promoter silences transcription in human prostate cancer. Cancer Res 2000; 60: 3623–30. [PubMed] [Google Scholar]
  • 24. Gonzalgo ML, Hayashida T, Bender CM, Pao MM, Tsai YC, Gonzales FA, Nguyen HD, Nguyen TT, Jones PA. The role of DNA methylation in expression of the p19/p16 locus in human bladder cancer cell lines. Cancer Res 1998; 58: 1245–52. [PubMed] [Google Scholar]
  • 25. Deng G, Chen A, Hong J, Chae HS, Kim YS. Methylation of CpG in a small region of the hMLHl promoter invariably correlates with the absence of gene expression. Cancer Res 1999; 59: 2029–33. [PubMed] [Google Scholar]
  • 26. 1 Methylation of hMLHl promoter correlates with the gene silencing with a region‐specific manner in colorectal cancer. Br J Cancer 2002; 86: 574–9. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27. Coignet LJ. Fluorescence in situ hybridization as a tool in molecular diagnostics of melanoma. In: Nickoloff BJ, editor. Melanoma techniques and protocols. Totowa : Humana Press; 2001. p. 181–91. [DOI] [PubMed] [Google Scholar]
  • 28. Clark SJ, Harrison J, Paul CL, Frommer M. High sensitivity mapping of methylated cytosines. Nucleic Acids Res 1994; 22: 2990–7. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29. 1 Methylation‐specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA 1996; 93: 9821–6. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30. Graff JR, Herman JG, Myohanen S, Baylin SB, Vertino PM. Mapping patterns of CpG island methylation in normal and neoplastic cells implicates both upstream and downstream regions in de novo methylation. J Biol Chem 1997; 272: 22322–9. [DOI] [PubMed] [Google Scholar]
  • 31. Hoare SF, Bryce LA, Wisman GB, Burns S, Going JJ, van der Zee AG, Keith WN. Lack of telomerase RNA gene hTERC expression in alternative lengthening of telomeres cells is associated with methylation of the hTERC promoter. Cancer Res 2001; 61: 27–32. [PubMed] [Google Scholar]
  • 32. Lapidus RG, Nass SJ, Butash KA, Parl FF, Weitzman SA, Graff JG, Herman JG, Davidson NE. Mapping of ER gene CpG island methylation‐specific polymerase chain reaction. Cancer Res 1998; 58: 2515–9. [PubMed] [Google Scholar]
  • 33. Esteller M, Corn PG, Urena JM, Gabrielson E, Baylin SB, Herman JG. Inactivation of glutathione S‐transferase PI gene by promoter hypermethylation in human neoplasia. Cancer Res 1998; 58: 4515–8. [PubMed] [Google Scholar]
  • 34. Zochbauer‐Muller S, Fong KM, Maitra A, Lam S, Geradts J, Ashfaq R, Virmani AK, Milchgrub S, Gazdar AF, Minna JD. 5′ CpG island methylation of the FHIT gene is correlated with loss of gene expression in lung and breast cancer. Cancer Res 2001; 61: 3581–5. [PubMed] [Google Scholar]
  • 35. Esteller M, Sparks A, Toyota M, Sanchez‐Cespedes M, Capella G, Peinado MA, Gonzalez S, Tarafa G, Sidransky D, Meltzer SJ, Baylin SB, Herman JG. Analysis of adenomatous polyposis coli promoter hypermethylation in human cancer. Cancer Res 2000; 60: 4366–71. [PubMed] [Google Scholar]
  • 36. Herman JG, Umar A, Polyak K, Graff JR, Ahuja N, Issa JP, Markowitz S, Willson JK, Hamilton SR, Kinzler KW, Kane MF, Kolodner RD, Vogelstein B, Kunkel TA, Baylin SB. Incidence and functional consequences of hMLHl promoter hypermethylation in colorectal carcinoma. Proc Natl Acad Sci USA 1998; 95: 6870–5. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37. Bachman KE, Herman JG, Corn PG, Merlo A, Costello JF, Cavenee WK, Baylin SB, Graff JR. Methylation‐associated silencing of the tissue inhibitor of metalloproteinase‐3 gene suggest a suppressor role in kidney, brain, and other human cancers. Cancer Res 1999; 59: 798–802. [PubMed] [Google Scholar]
  • 38. Miyamoto K, Asada K, Fukutomi T, Okochi E, Yagi Y, Hasegawa T, Asahara T, Sugimura T, Ushijima T. Methylation‐associated silencing of heparan sulfate D‐glucosaminyl 3‐O‐sulfotransferase‐2 (3‐OST‐2) in human breast, colon, lung and pancreatic cancers. Oncogene 2003; 22: 274–80. [DOI] [PubMed] [Google Scholar]
  • 39. Kaneda A, Kaminishi M, Yanagihara K, Sugimura T, Ushijima T. Identification of silencing of nine genes in human gastric cancers. Cancer Res 2002; 62: 6645–50. [PubMed] [Google Scholar]
  • 40. Toyota M, Ahuja N, Suzuki H, Itoh F, Ohe‐Toyota M, Imai K, Baylin SB, Issa JP. Aberrant methylation in gastric cancer associated with the CpG island methylator phenotype. Cancer Res 1999; 59: 5438–42. [PubMed] [Google Scholar]
  • 41. Yamashita K, Dai T, Dai Y, Yamamoto F, Perucho M. Genetics supersedes epigenetics in colon cancer phenotype. Cancer Cell 2003; 4: 121–31. [DOI] [PubMed] [Google Scholar]
  • 42. 1 PTEN signaling pathways in melanoma. Oncogene 2003; 22: 3113–22. [DOI] [PubMed] [Google Scholar]
  • 43. Nakagawachi T, Soejima H, Urano T, Zhao W, Higashimoto K, Satoh Y, Matsukura S, Kudo S, Kitajima Y, Harada H, Furukawa K, Matsuzaki H, Emi M, Nakabeppu Y, Miyazaki K, Sekiguchi M, Mukai T. Silencing effect of CpG island hypermethylation and histone modifications on O6‐methylguanine‐DNA methyltransferase (MGMT) gene expression in human cancer. Oncogene 2003; 22: 8835–44. [DOI] [PubMed] [Google Scholar]
  • 44. Domann FE, Rice JC, Hendrix MJ, Futscher BW. Epigenetic silencing of maspin gene expression in human breast cancers. Int J Cancer 2000; 85: 805–10. [DOI] [PubMed] [Google Scholar]
  • 45. 1 Role for DNA methylation in the control of cell type specific maspin expression. Nat Genet 2002; 31: 175–9. [DOI] [PubMed] [Google Scholar]
  • 46. Wada K, Maesawa C, Akasaka T, Masuda T. Aberrant expression of the maspin gene associated with epigenetic modification in melanoma cells. J Invest Dematol 2004; 122: 805–11. [DOI] [PubMed] [Google Scholar]
  • 47. Kaneda A, Wakazono K, Tsukamoto T, Yagi Y, Tatematsu M, Kaminishi M, Sugimura T, Ushijima T. Lysyl oxidase is a tumor‐suppressor gene inactivated by methylation and loss of heterozygosity in human gastric cancers. Cancer Res 2004; 64: 6410–5. [DOI] [PubMed] [Google Scholar]
  • 48. Zendman AJ, de Wit NJ, van Kraats AA, Weidle UH, Ruiter DJ, van Muijen GN. Expression profile of genes coding for melanoma differentiation antigens and cancer/testis antigens in metastatic lesions of human cutaneous melanoma. Melanoma Res 2001; 11: 451–9. [DOI] [PubMed] [Google Scholar]

Articles from Cancer Science are provided here courtesy of Wiley

RESOURCES